<DOC>
	<DOC>NCT02986373</DOC>
	<brief_summary>This is an open-label extension (OLE) study to assess the efficacy, safety and tolerability of risankizumab in subjects with psoriatic arthritis (PsA) who have completed all doses of study drug and the Week 24 visit of Study 1311.5 (Phase 2 randomized control trial in PsA subjects, sponsored by Boehringer Ingelheim).</brief_summary>
	<brief_title>A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study 1311.5</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<criteria>Subjects who have completed all doses of study drug and Week 24 visit of Study 1311.5. Women of childbearing potential who are sexually active, must agree to use at least one accepted method of contraception throughout the study, including 16 weeks after last dose of study drug is given. Women of childbearing potential must have a negative urine pregnancy test at Baseline (Week 0/V1). Subjects must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any study specific procedures. Subject is judged to be in good health as determined by the Investigator. Female subject who is pregnant, breastfeeding or is considering becoming pregnant during study participation, including 16 weeks after the last dose of study drug is given. Premature discontinuation of the study drug in Study 1311.5 for any reason. Use of a biologic treatment other than risankizumab since first dose of study drug in Study 1311.5. Time elapsed is &gt; 8 weeks since the Week 24 visit in Study 1311.5. Active systemic infections during the last 2 weeks (exception: common cold) prior to the first dose, as assessed by the investigator.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ABBV-066</keyword>
	<keyword>risankizumab</keyword>
	<keyword>BI655066</keyword>
</DOC>